The University of Chicago Header Logo

Connection

Ezra Cohen to Immunotherapy

This is a "connection" page, showing publications Ezra Cohen has written about Immunotherapy.
Connection Strength

1.609
  1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 07 15; 7(1):184.
    View in: PubMed
    Score: 0.458
  2. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18).
    View in: PubMed
    Score: 0.404
  3. Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence. Clin Cancer Res. 2024 Apr 01; 30(7):1232-1239.
    View in: PubMed
    Score: 0.159
  4. Inevitable Progress-Relying on the Immune System, Not Chance. Clin Cancer Res. 2022 02 01; 28(3):435-437.
    View in: PubMed
    Score: 0.135
  5. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491.
    View in: PubMed
    Score: 0.112
  6. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223.
    View in: PubMed
    Score: 0.111
  7. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271.
    View in: PubMed
    Score: 0.095
  8. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jan 01; 10(1):32-41.
    View in: PubMed
    Score: 0.039
  9. Patient selection for immunotherapy in head and neck cancer - Authors' reply. Lancet Oncol. 2021 07; 22(7):e291-e292.
    View in: PubMed
    Score: 0.033
  10. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
    View in: PubMed
    Score: 0.032
  11. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res. 2020 10 01; 26(19):5153-5161.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.